Egetis Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Egetis Therapeutics has a total shareholder equity of SEK401.5M and total debt of SEK108.9M, which brings its debt-to-equity ratio to 27.1%. Its total assets and total liabilities are SEK646.6M and SEK245.1M respectively.
Key information
27.1%
Debt to equity ratio
SEK 108.90m
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 192.60m |
| Equity | SEK 401.50m |
| Total liabilities | SEK 245.10m |
| Total assets | SEK 646.60m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: EGTXS's short term assets (SEK232.5M) exceed its short term liabilities (SEK149.2M).
Long Term Liabilities: EGTXS's short term assets (SEK232.5M) exceed its long term liabilities (SEK95.9M).
Debt to Equity History and Analysis
Debt Level: EGTXS has more cash than its total debt.
Reducing Debt: EGTXS's debt to equity ratio has increased from 0% to 27.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EGTXS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EGTXS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.